July was yet another bumper month for pharma, which saw France-based Sanofi ink a $2bn deal with Skyhawk Therapeutics to develop small molecule drugs for oncology and immunology. (Also see "Sanofi Continues Hunt For External Innovation With Skyhawk Deal" - Scrip, 6 July, 2022.)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?